US 11,685,782 B2
Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy
Yang Shi, Newton, MA (US); Wanqiang Sheng, Allston, MA (US); Arlene H. Sharpe, Brookline, MA (US); and Martin W. LaFleur, Boston, MA (US)
Assigned to Children's Medical Center Corporation, Boston, MA (US); and President & Fellows of Harvard College, Cambridge, MA (US)
Appl. No. 16/758,474
Filed by Children's Medical Center Corporation, Boston, MA (US); and President & Fellows of Harvard College, Cambridge, MA (US)
PCT Filed Oct. 23, 2018, PCT No. PCT/US2018/057058
§ 371(c)(1), (2) Date Apr. 23, 2020,
PCT Pub. No. WO2019/083971, PCT Pub. Date May 2, 2019.
Claims priority of provisional application 62/688,002, filed on Jun. 21, 2018.
Claims priority of provisional application 62/576,001, filed on Oct. 23, 2017.
Prior Publication US 2020/0255527 A1, Aug. 13, 2020
Int. Cl. C07K 16/28 (2006.01); A61P 35/00 (2006.01); C12N 15/113 (2010.01); A61K 39/00 (2006.01)
CPC C07K 16/2818 (2013.01) [A61P 35/00 (2018.01); C07K 16/2827 (2013.01); C12N 15/1137 (2013.01); A61K 2039/505 (2013.01)] 21 Claims
OG exemplary drawing
 
1. A method of treating cancer in a patient, the method comprising:
administering to a patient in need thereof a therapeutically effective amount of a lysine-specific demethylase 1A (LSD1) inhibitor to thereby treat cancer in the patient, wherein the LSD1 inhibitor comprises an inhibitory nucleic acid comprising SEQ ID NO: 2.